Oncotelic's Nanotech Paper: A Blueprint for De-risking Drug Assets

AGOURA HILLS, CA – July 22, 2026 – In the world of biotechnology, a peer-reviewed publication can be much more than an academic milestone. For Oncotelic Therapeutics (OTCQB: OTLC) and its affiliate Sapu Nano, their recent paper in Biomedicines is exactly that: a meticulously detailed business case disguised as a scientific manuscript. The publication validates the technology behind Sapu003, an intravenous (IV) version of the established cancer drug everolimus, but the story behind the numbers reveals a strategic de-risking of a technology platform with implications far beyond a single product.

At its core, the announcement details one of the most comprehensive preclinical data packages ever reported for an IV everolimus formulation. This isn't just about proving a new drug delivery method works in theory; it's about proving it's practical, safe, and, most importantly, manufacturable at scale. For investors and potential pharmaceutical partners, this kind of data package is the bedrock of valuation, transforming a promising concept into a tangible asset with a clearer path to market.

From Lab Concept to Manufacturing Reality

The challenge with everolimus, a widely used mTOR inhibitor marketed orally as Afinitor®, has always been its difficult pharmacology. Oral administration leads to poor and erratic absorption—only about 10% of the drug makes it into the bloodstream—and significant gastrointestinal side effects that can force patients to discontinue treatment. Oncotelic and Sapu Nano's solution, Sapu003, uses the proprietary Deciparticle™ platform to bypass these issues entirely via intravenous delivery.

The new publication provides the critical evidence that this solution is viable. It isn't a single, isolated study but a complete translational dossier covering everything the FDA wants to see before a drug enters later-stage human trials. This includes:

• ADME and Pharmacokinetics (PK): A full breakdown of how the body absorbs, distributes, metabolizes, and excretes the drug. The findings confirm Sapu003 achieves 100% bioavailability with broad systemic distribution, avoiding the gut concentration that plagues the oral version.
• GLP Toxicology: Formal safety studies conducted under Good Laboratory Practice standards showed no treatment-related gastric damage, directly addressing the key tolerability concerns of oral everolimus.
• cGMP Manufacturing: Crucially, the paper documents a reproducible manufacturing process compliant with current Good Manufacturing Practices (cGMP). This is a monumental hurdle in nanomedicine. Many novel formulations die in the lab because they can't be produced consistently and cost-effectively. Demonstrating a scalable cGMP process is a powerful signal of commercial readiness.

"This publication represents a significant milestone in the clinical translation of the Deciparticle™ platform," said Vuong Trieu, Ph.D., CEO of Oncotelic Therapeutics, in the company's press release. He emphasized that the work brings together the "complete scientific package" supporting the ongoing Phase 1b clinical trial (NCT07369505). This is the language of risk mitigation, assuring the market that the foundational science and manufacturing are sound.

The Deciparticle™ Engine: More Than a One-Off Fix

While Sapu003 is the immediate focus, the real long-term value story lies in the Deciparticle™ platform itself. This is not a single solution for a single drug but a versatile engine for value creation. The technology is designed to formulate poorly water-soluble compounds—a notoriously difficult class of molecules that make up a large portion of the pharmaceutical pipeline—into stable IV therapies.

Sapu Nano has reported a 90% success rate in formulating over 100 different active pharmaceutical ingredients (APIs) with the platform. This transforms the technology from a product into a strategic asset. It opens the door to a pipeline of reformulated, improved drugs and creates opportunities for lucrative strategic partnerships with companies struggling to deliver their own hydrophobic compounds. The advancement of a second candidate, Sapu006 (a novel docetaxel formulation), into clinical trials underscores this broader utility.

This platform strategy is a hallmark of Dr. Trieu, a co-inventor of Abraxane®, the groundbreaking nanoparticle chemotherapy that turned a difficult-to-administer drug, paclitaxel, into a blockbuster. The playbook is familiar: take a proven therapeutic agent, re-engineer its delivery mechanism to improve safety and efficacy, and unlock a new tier of clinical and commercial value. The comprehensive validation of Sapu003 serves as a powerful proof-of-concept for the entire Deciparticle™ platform.

Redefining the Market for a Proven Therapy

For patients with advanced mTOR-sensitive solid tumors, the clinical implications are profound. An IV everolimus that provides predictable dosing and avoids debilitating gastrointestinal toxicity could become a superior treatment option. But the potential benefits may go even further. By achieving higher, more consistent drug exposure, Sapu003 is designed to induce dual inhibition of both mTORC1 and mTORC2 complexes. According to drug development experts, this could shift everolimus's effect from merely cytostatic (slowing tumor growth) to cytotoxic (actively killing cancer cells), potentially leading to more significant tumor shrinkage where the oral version has shown limited efficacy.

This potential for enhanced efficacy, combined with the recent identification of a biomarker to predict patient sensitivity, positions Sapu003 not just as a replacement but as a significant upgrade. If the ongoing Phase 1b study confirms these preclinical advantages, Sapu003 could capture a significant share of the multi-billion dollar mTOR inhibitor market and expand its use into new indications.

The Strategic Blueprint: AI, Automation, and Asset Value

The Sapu003 milestone does not exist in a vacuum. It slots perfectly into Oncotelic's broader vision of transforming pharmaceutical development and manufacturing. The company is simultaneously advancing its PDAOAI artificial intelligence platform, which is designed to accelerate drug discovery and, more critically, automate GMP manufacturing.

Oncotelic's recent initiatives with TechForce Robotics to create an AI-powered GMP manufacturing platform show a clear ambition to tackle one of the industry's biggest challenges. The successful development of a robust cGMP process for a complex nanomedicine like Sapu003 provides an invaluable real-world data set and proof point for these automation efforts. It demonstrates a core competency in manufacturing that now serves as the foundation for a much larger technology play.

By validating the science, manufacturing, and safety of its lead asset, Oncotelic has not just advanced a drug candidate. It has validated a platform, strengthened its strategic narrative, and laid a crucial piece of groundwork for an ecosystem that integrates novel drug delivery with next-generation automated manufacturing.